Skip to main content
SpringerLink
Log in

Vitreoretinal Lymphoma: Staging and Treatment

  • Chapter
  • First Online:
Ocular and Adnexal Lymphoma

Part of the book series: Essentials in Ophthalmology ((ESSENTIALS))

  • 1012 Accesses

Abstract

Staging and treatment of primary vitreoretinal lymphoma (PVRL) are based upon the understanding that PVRL is a variant of primary central nervous system lymphoma (PCNSL). Approximately 56–85 % of individuals initially diagnosed with PVRL will subsequently develop central nervous system (CNS) involvement over a period of many months to several years. Conversely, about 25 % of patients with PCNSL will have detectable intraocular involvement at the time of diagnosis. There is a general consensus that regimens containing high-dose methotrexate, with or without whole-brain radiation therapy (WBRT), yield better response rates and outcomes than regimens that do not contain high-dose methotrexate. Disease relapse in the CNS is a major issue, particularly after local treatment with ocular radiotherapy or intravitreal chemotherapy. Management should be undertaken by a multidisciplinary team of experts in the fields of ophthalmic oncology, pathology, radiation oncology, and neuro-oncology for optimal treatment planning and for continued patient surveillance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abrey LE, Moskowitz CH, Mason WP et al (2003) Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 21(22):4151–4156

    Article  PubMed  CAS  Google Scholar 

  • Abrey LE, Ben-Porat L, Panageas KS et al (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24(36):5711–5715

    Article  PubMed  Google Scholar 

  • Akpek EK, Ahmed I, Hochberg FH et al (1999) Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology 106(9):1805–1810

    Article  PubMed  CAS  Google Scholar 

  • Angelov L, Doolittle ND, Kraemer DF et al (2009) Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol 27(21):3503–3509

    Article  PubMed  CAS  Google Scholar 

  • Bataille B, Delwail V, Menet E et al (2000) Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 92(2):261–266

    Article  PubMed  CAS  Google Scholar 

  • Batchelor TT, Kolak G, Ciordia R et al (2003) High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 9(2):711–715

    PubMed  CAS  Google Scholar 

  • Blay JY, Conroy T, Chevreau C et al (1998) High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16(3):864–871

    PubMed  CAS  Google Scholar 

  • Chang CC, Kampalath B, Schultz C et al (2003) Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Arch Pathol Lab Med 127(2):208–212

    PubMed  Google Scholar 

  • Char DH, Ljung BM, Miller T, Phillips T (1988) Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmology 95(5):625–630

    PubMed  CAS  Google Scholar 

  • Chimienti E, Spina M, Vaccher E, Tirelli U (2009) Management of immunocompetent patients with primary central nervous system lymphoma. Clin Lymphoma Myeloma 9(5):353–364

    Article  PubMed  CAS  Google Scholar 

  • Correa DD, DeAngelis LM, Shi W et al (2004) Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62(4):548–555

    Article  PubMed  CAS  Google Scholar 

  • Deangelis LM, Hormigo A (2004) Treatment of primary central nervous system lymphoma. Semin Oncol 31(5):684–692

    Article  PubMed  Google Scholar 

  • DeAngelis LM, Yahalom J, Heinemann MH et al (1990) Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 40(1):80–86

    Article  PubMed  CAS  Google Scholar 

  • DeAngelis LM, Seiferheld W, Schold SC et al (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20(24):4643–4648

    Article  PubMed  Google Scholar 

  • Doucet S, Kumthekar P, Raizer J (2013) Primary Central Nervous System Lymphoma. Curr Treat Options Oncol 14(2):185–197

    Article  PubMed  Google Scholar 

  • Ferreri AJ, Blay JY, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21(2):266–272

    Article  PubMed  Google Scholar 

  • Freeman LN, Schachat AP, Knox DL et al (1987) Clinical features, laboratory investigations, and survival in ocular reticulum cell sarcoma. Ophthalmology 94(12):1631–1639

    PubMed  CAS  Google Scholar 

  • Frenkel S, Hendler K, Siegal T et al (2008) Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol 92(3):383–388

    Article  PubMed  CAS  Google Scholar 

  • Galor A, Ference SJ, Singh AD et al (2007) Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma. Am J Ophthalmol 144(1):45–49

    Article  PubMed  Google Scholar 

  • Gerstner ER, Carson KA, Grossman SA, Batchelor TT (2008) Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology 70(5):401–402

    Article  PubMed  Google Scholar 

  • Grimm SA, Pulido JS, Jahnke K et al (2007) Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol 18(11):1851–1855

    Article  PubMed  CAS  Google Scholar 

  • Herrlinger U, Schabet M, Bitzer M et al (1999) Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurooncol 43(3):219–226

    Article  PubMed  CAS  Google Scholar 

  • Hochberg FH, Miller DC (1988) Primary central nervous system lymphoma. J Neurosurg 68(6):835–853

    Article  PubMed  CAS  Google Scholar 

  • Itty S, Pulido JS (2009) Rituximab for intraocular lymphoma. Retina 29(2):129–132

    Article  PubMed  Google Scholar 

  • Kiewe P, Fischer L, Martus P et al (2010) Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort. Neuro Oncol 12(4):409–417

    Article  PubMed  Google Scholar 

  • Margolis L, Fraser R, Lichter A, Char DH (1980) The role of radiation therapy in the management of ocular reticulum cell sarcoma. Cancer 45(4):688–692

    Article  PubMed  CAS  Google Scholar 

  • Omuro AM, DeAngelis LM, Yahalom J, Abrey LE (2005) Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 64(1):69–74

    Article  PubMed  CAS  Google Scholar 

  • Peterson K, Gordon KB, Heinemann MH, DeAngelis LM (1993) The clinical spectrum of ocular lymphoma. Cancer 72(3):843–849

    Article  PubMed  CAS  Google Scholar 

  • Sandor V, Stark-Vancs V, Pearson D et al (1998) Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 16(9):3000–3006

    PubMed  CAS  Google Scholar 

  • Singh AD, Peereboom DM (2007) Intraocular rituximab. Eye 21(12):1453–1454

    Article  PubMed  CAS  Google Scholar 

  • Singh AD, Lewis H, Schachat AP (2005) Primary lymphoma of the central nervous system. Ophthalmol Clin North Am 18(1):199–207, x

    Article  PubMed  Google Scholar 

  • Smith JR, Rosenbaum JT, Wilson DJ et al (2002) Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 109(9):1709–1716

    Article  PubMed  Google Scholar 

  • Soussain C, Suzan F, Hoang-Xuan K et al (2001) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19(3):742–749

    PubMed  CAS  Google Scholar 

  • Soussain C, Hoang-Xuan K, Taillandier L et al (2008) Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 26(15):2512–2518

    Article  PubMed  Google Scholar 

  • Whitcup SM, de Smet MD, Rubin BI et al (1993) Intraocular lymphoma. Clinical and histopathologic diagnosis. Ophthalmology 100(9):1399–1406

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Ave R35, Cleveland, OH, 44195, USA

    Mary E. Aronow MD & Arun D. Singh MD

  2. The Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic Foundation, 9500 Euclid Ave R35, Cleveland, OH, 44195, USA

    David M. Peereboom MD

Authors
  1. Mary E. Aronow MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arun D. Singh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David M. Peereboom MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David M. Peereboom MD .

Editor information

Editors and Affiliations

  1. Dept. of Ophthalmic Oncology, Cole Eye Institute Cleveland Clinic Foundation, Cleveland, Ohio, USA

    Arun D. Singh

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Aronow, M.E., Singh, A.D., Peereboom, D.M. (2014). Vitreoretinal Lymphoma: Staging and Treatment. In: Singh, A. (eds) Ocular and Adnexal Lymphoma. Essentials in Ophthalmology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-38499-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-38499-8_8

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-38498-1

  • Online ISBN: 978-3-642-38499-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation